N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide
C23H25N7O2 — CID 146161498
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide
N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide (PubChem CID 146161498) has the molecular formula C23H25N7O2 and a molecular weight of 431.50 g/mol. Its IUPAC name is N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide.
Molecular Properties
| Compound Name | N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide |
|---|---|
| PubChem CID | 146161498 |
| Molecular Formula | C23H25N7O2 |
| Molecular Weight | 431.50 g/mol |
| Exact Mass | 431.21 |
| IUPAC Name | N-[5-[2-(dimethylamino)ethylcarbamoyl]-3-pyridinyl]-6-(1-methylpyrrol-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide |
| SMILES | CN(C)CCNC(=O)c1cncc(NC(=O)c2cnn3cc(-c4ccn(C)c4)ccc23)c1 |
| InChI | InChI=1S/C23H25N7O2/c1-28(2)9-7-25-22(31)18-10-19(12-24-11-18)27-23(32)20-13-26-30-15-16(4-5-21(20)30)17-6-8-29(3)14-17/h4-6,8,10-15H,7,9H2,1-3H3,(H,25,31)(H,27,32) |
| InChIKey | GHHXSJPIIIDTPI-UHFFFAOYSA-N |
| XLogP | 2.28 |
| TPSA | 96.56 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 431.50 |
| LogP ≤ 5 | 2.28 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146161498 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.